Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 4/2014

01-04-2014 | Short Communication

Role of eye’s sign in patients with neuropsychiatric disorders of systemic lupus erythematosus

Author: Rui Wu

Published in: Rheumatology International | Issue 4/2014

Login to get access

Abstract

To investigate role of eye’s sign in the patients with neuropsychiatric systemic lupus erythematosus (NPSLE). The scores of eye’s sign in bulbar conjunctival microvascular changes were assessed in all patients according to our criteria. The disease activity was measured with SLE Disease Activity Index (SLEDAI) score. Anticardiolipin antibody (aCL) and hemorheology were performed in patients. The eye’s sign and whole-blood viscosity were significantly higher in NPSLE patients than those in non-NPSLE patients. The eye’s sign has a correlation with SLEDAI, disease duration, whole-blood viscosity, serum concentration of aCL, and no correlation with erythrocyte sedimentation rate, complement and titre of ANA (Anti-nuclear antibody). Our results suggest that eye’s sign plays an important role in active NPSLE. The continuous disease activity promotes the vascular damage through an increasing blood viscosity and the eye’s sign reflects well this condition. Checking the eye’s sign is an useful indicator in assessment of activity or that of effectiveness in treating (NP)SLE.
Literature
1.
Li GX (1988) Study on eye-signs in blood stasis syndrome. J Integr Tradit Chin West Med 8(10):630
2.
Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
3.
ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRef
4.
Rui Wu, Jiangxiang X, Fengda Z et al (2011) Modernized study on eye’s sign in blood stasis. Chinese Journal of Integrated Traditional and Western Medicine. 31(3):319–322
5.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Committee on Prognosis Studies in SLE: derivation of the SLEDAI: a disease activity index for lupus patients. J Arthritis Rheum 35:630–640CrossRef
6.
Minagar A, Alexander JS (2003) Blood-brain barrier disruption in multiple scelrosis. J Mult. Scler. 9:540–549CrossRef
7.
Rice JS, Kowal C, Volpe BT, DeGiorgio LA, Diamond B (2005) Molecular mimicry: anti-DNA antibodies bind mircrobial and nonnucleic acid self-antigens. J Curr Top Microbiol Immunol 296:137–151
8.
Silber HA, Bluemke DA, Ouyang P, Du VP, Post WS, Lima JA (2001) The relationship between vascular wall shear stress and flow-mediated dilation: endothelial function assessed by phase-contrast magnetic resonance angiography. J Am Coil Cardiol 38:1859–1865CrossRef
9.
Afeltra A, Garzia P, Mitterhofer AP et al (2003) Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. J Neurol 61(1):108–110
Metadata
Title
Role of eye’s sign in patients with neuropsychiatric disorders of systemic lupus erythematosus
Author
Rui Wu
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 4/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2802-4

Other articles of this Issue 4/2014

Rheumatology International 4/2014 Go to the issue

Short Communication

Alpha 1-antitrypsin activity is markedly decreased in Wegener’s granulomatosis

Short Communication

Osseous sarcoid with lytic lesions in skull

Letter to the Editors

Poor accuracy of anti-citrulline antibody test in diagnosis of rheumatoid arthritis in Iran

Original Article

Efficacy of EMLA cream phonophoresis comparison with ultrasound therapy on myofascial pain syndrome of the trapezius: a single-blind, randomized clinical study

Review Article

Databases and registers: useful tools for research, no studies

Letter to the Editor

Lack of association of the autophagy-related gene polymorphism ATG16L1 rs2241880 in RA predisposition
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits